IP Group is among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.
Artios Pharma, a UK-based cancer therapy developer, secured $153m in a series C round on Tuesday from investors including commercialisation firm IP Group.
Investment firms Omega Funds and TCG Crossover co-led the round, which included the corporate venture capital units of pharmaceutical firms Merck Group, Novartis and Pfizer – M Ventures, Novartis Venture Fund and Pfizer Ventures.
Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital…
